- Home
- INCY vs MMYT Comparison
INCY vs MMYT Comparison
Compare INCY & MMYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- MMYT
- Stock Information
- Founded
- INCY 1991
- MMYT 2000
- Country
- INCY United States
- MMYT India
- Employees
- INCY N/A
- MMYT N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- MMYT Transportation Services
- Sector
- INCY Health Care
- MMYT Consumer Discretionary
- Exchange
- INCY Nasdaq
- MMYT Nasdaq
- Market Cap
- INCY 13.4B
- MMYT 10.7B
- IPO Year
- INCY 1993
- MMYT 2010
- Fundamental
- Price
- INCY $58.21
- MMYT $103.30
- Analyst Decision
- INCY Hold
- MMYT Strong Buy
- Analyst Count
- INCY 20
- MMYT 2
- Target Price
- INCY $74.00
- MMYT $122.50
- AVG Volume (30 Days)
- INCY 2.3M
- MMYT 863.9K
- Earning Date
- INCY 04-29-2025
- MMYT 05-14-2025
- Dividend Yield
- INCY N/A
- MMYT N/A
- EPS Growth
- INCY N/A
- MMYT 313.68
- EPS
- INCY 0.15
- MMYT 1.89
- Revenue
- INCY $4,241,216,999.00
- MMYT $935,761,000.00
- Revenue This Year
- INCY $12.21
- MMYT $29.58
- Revenue Next Year
- INCY $9.20
- MMYT $20.71
- P/E Ratio
- INCY $345.39
- MMYT $54.76
- Revenue Growth
- INCY 14.76
- MMYT 28.51
- 52 Week Low
- INCY $50.35
- MMYT $60.55
- 52 Week High
- INCY $83.95
- MMYT $123.00
- Technical
- Relative Strength Index (RSI)
- INCY 40.69
- MMYT 55.96
- Support Level
- INCY $57.05
- MMYT $85.00
- Resistance Level
- INCY $59.95
- MMYT $103.53
- Average True Range (ATR)
- INCY 2.76
- MMYT 5.80
- MACD
- INCY 0.18
- MMYT 0.85
- Stochastic Oscillator
- INCY 46.45
- MMYT 96.10
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About MMYT MakeMyTrip Limited
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.